MedTrace Logo

The Biomarker Prediction Model of Septic Risk in Infected Patients

NCT05095324 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2021-10-27

No results posted yet for this study

Summary

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to an infection. Sepsis is associated with high mortality because of the complex mechanisms. In China, the mortality of sepsis in ICU was up to 35.5%. As a major and urgent global public health challenge，sepsis is hard to treat because of the complexion and highly heterogeneous in clinical manifestation. The early diagnosis and stratification of the infection is very important. If we can identify the patients who may developed into the sepsis, the therapeutic regimen was not only antibiotic, but also included stable the vascular endothelial cells，regulation of coagulation function and protection of organ functions. Biomarkers have an important place in sepsis because they are strictly related to the organ damage. Each organ has its own specific biomarkers, and these biomarkers will change according to the severity of the disease. So the investigators want to find the difference of biomarkers of each organ in patients from infection to spesis.

Conditions

  • Sepsis
  • Early Diagnosis
  • Biomarkers

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    collaborator OTHER

  • First Hospital of Tsinghua University

    collaborator OTHER

  • Renmin Hospital of Wuhan University

    collaborator OTHER

  • Hebei Medical University Third Hospital

    collaborator OTHER

  • Tianjin Medical University General Hospital

    collaborator OTHER

  • Beijing Tsinghua Chang Gung Hospital

    lead OTHER

Principal Investigators

  • Wang zhong, master · Beijing Tsinghua Chang Gung Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-07
Primary Completion
2022-09-07
Completion
2022-09-14

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05095324 on ClinicalTrials.gov